Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands

Journal of Medicinal Chemistry

Volumn 57, Issue 10, 2014, Pages 4239-4251

  Bai, Suping ^a,b   Li, Shihong ^a   Xu, Jinbin ^a   Peng, Xin ^a   Sai, Kiran ^a   Chu, Wenhua ^a   Tu, Zhude ^a   Zeng, Chenbo ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AMIDE; BENZAMIDE DERIVATIVE; CYTOTOXIC AGENT; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (2 METHOXYBENZYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (2 METHOXYPHENYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (3 HYDROXYBENZYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (3 METHOXYBENZYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (3 METHOXYPHENYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (4 HYDROXYBENZYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (4 METHOXYBENZYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 (4 METHOXYPHENYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 [2 (2 FLUOROETHOXY)PHENYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 [3 (2 FLUOROETHOXY)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 [3 (2 FLUOROETHOXY)PHENYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 [4 (2 FLUOROETHOXY)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUTYL] 1 [4 (2 FLUOROETHOXY)PHENYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL] 1 (2 METHOXYBENTHYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL] 1 (2 METHOXYPHENYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL] 1 (3 METHOXYBENTHYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL] 1 (3 METHOXYPHENYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL] 1 (4 METHOXYBENTHYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL] 1 (4 METHOXYPHENYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL] 4 ETHYNYLBENZAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL] 4 [1 (2 FLUOROETHYL) 1H 1,2,3 TRIAZOL 4 YL]BENZAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL] 4 [1 (2 METHOXYBENZYL) 1H 1,2,3 TRIAZOL 4 YL]BENZAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL] 4 [1 [2 (2 FLUOROETHOXY)ETHYL] 1H 1,2,3 TRIAZOL 4 YL]BENZAMIDE; N [4 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL] 4 [1 [2 [2 (2 FLUOROETHOXY)ETHOXY]ETHYL] 1H 1,2,3 TRIAZOL 4 YL]BENZAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; GUINEA PIGS; LIGANDS; MICE; MOLECULAR CONFORMATION; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84901273829     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5001453     Document Type: Article

References (68)

1. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog J. Pharmacol. Exp. Ther. 1976, 197, 517-532
2. 3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: A comparative study Brain Res. 1992, 581, 33-38
3. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: Characterization by ligand binding and photoaffinity labeling Eur. J. Pharmacol. 1994, 268, 9-18
4. Hellewell, S. B.; Bowen, W. D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain Brain Res. 1990, 527, 244-253
5. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T.-P.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites Trends Pharmacol. Sci. 1992, 13, 85-86
6. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.; Striessnig, J.; Kempner, E.; Glossmann, H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8072-8077
7. Seth, P.; Leibach, F. H.; Ganapathy, V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor Biochem. Biophys. Res. Commun. 1997, 241, 535-540
8. Kekuda, R.; Prasad, P. D.; Fei, Y. J.; Leibach, F. H.; Ganapathy, V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1) Biochem. Biophys. Res. Commun. 1996, 229, 553-558
9. Narayanan, S.; Bhat, R.; Mesangeau, C.; Poupaert, J. H.; McCurdy, C. R. Early development of sigma-receptor ligands Future Med. Chem. 2011, 3, 79-94
10. Bowen, W. D. Sigma receptors: Recent advances and new clinical potentials Pharm. Acta Helv. 2000, 74, 211-8
11. Maurice, T.; Su, T.-P. The pharmacology of sigma-1 receptors Pharmacol. Ther. 2009, 124, 195-206
12. Tsai, S. Y.; Rothman, R. K.; Su, T. P. Insights into the sigma-1 receptor chaperone's cellular functions: a microarray report Synapse 2012, 66, 42-51
13. Takebayashi, M.; Hayashi, T.; Su, T. P. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: Implications for antidepressants J. Pharmacol. Exp. Ther. 2002, 303, 1227-1237
14. Hayashi, T.; Tsai, S. Y.; Mori, T.; Fujimoto, M.; Su, T. P. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders Expert Opin. Ther. Targets 2011, 15, 557-577
15. Fishback, J. A.; Robson, M. J.; Xu, Y. T.; Matsumoto, R. R. Sigma receptors: potential targets for a new class of antidepressant drug Pharmacol. Ther. 2010, 127, 271-282
16. Robson, M. J.; Noorbakhsh, B.; Seminerio, M. J.; Matsumoto, R. R. Sigma-1 receptors: potential targets for the treatment of substance abuse Curr. Pharm. Des 2012, 18, 902-919
17. Niitsu, T.; Iyo, M.; Hashimoto, K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases Curr. Pharm. Des 2012, 18, 875-883
18. Kunitachi, S.; Fujita, Y.; Ishima, T.; Kohno, M.; Horio, M.; Tanibuchi, Y.; Shirayama, Y.; Iyo, M.; Hashimoto, K. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors Brain Res. 2009, 1279, 189-196
19. Hashimoto, K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship Cent. Nerv. Syst. Agents Med. Chem. 2009, 9, 197-204
20. Kulkarni, S. K.; Dhir, A. Sigma-1 receptors in major depression and anxiety Expert Rev. Neurother. 2009, 9, 1021-1034
21. 1)-receptor in the acute behavioral effects of antidepressants J. Pharmacol. Sci. 2011, 115, 279-292
22. Crawford, K. W.; Coop, A.; Bowen, W. D. Sigma-2 receptors regulate changes in sphingolipid levels in breast tumor cells Eur. J. Pharmacol. 2002, 443, 207-9
23. Vilner, B. J.; Bowen, W. D. Modulation of cellular calcium by sigma-2 receptors: Release from intracellular stores in human SK-N-SH neuroblastoma cells J. Pharmacol. Exp. Ther. 2000, 292, 900-911
24. Cassano, G.; Gasparre, G.; Contino, M.; Niso, M.; Berardi, F.; Perrone, R.; Colabufo, N. A. The sigma-2 receptor agonist PB28 inhibits calcium release from the endoplasmic reticulum of SK-N-SH neuroblastoma cells Cell Calcium 2006, 40, 23-28
25. 2+ efflux from the endoplasmic reticulum and mitochondria in SK-N-SH cells Cell Calcium 2009, 45, 340-345
26. + channels in the heart J. Pharmacol. Exp. Ther. 2007, 322, 341-350
27. Haller, J. L.; Panyutin, I.; Chaudhry, A.; Zeng, C.; Mach, R. H.; Frank, J. A. Sigma-2 receptor as potential indicator of stem cell differentiation Mol. Imaging Biol. 2012, 14, 325-335
28. Xu, J.; Zeng, C.; Chu, W.; Pan, F.; Rothfuss, J. M.; Zhang, F.; Tu, Z.; Zhou, D.; Zeng, D.; Vangveravong, S.; Johnston, F.; Spitzer, D.; Chang, K. C.; Hotchkiss, R. S.; Hawkins, W. G.; Wheeler, K. T.; Mach, R. H. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site Nat. Commun. 2011, 2, 380
29. Crawford, K. W.; Bowen, W. D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines Cancer Res. 2002, 62, 313-322
30. Ostenfeld, M. S.; Fehrenbacher, N.; Hoyer-Hansen, M.; Thomsen, C.; Farkas, T.; Jaattela, M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress Cancer Res. 2005, 65, 8975-8983
31. Rybczynska, A. A.; Dierckx, R. A.; Ishiwata, K.; Elsinga, P. H.; van Waarde, A. Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation J. Nucl. Med. 2008, 49, 2049-2056
32. Hornick, J. R.; Vangveravong, S.; Spitzer, D.; Abate, C.; Berardi, F.; Goedegebuure, P.; Mach, R. H.; Hawkins, W. G. Lysosomal membrane permeabilization is an early event in sigma-2 receptor ligand mediated cell death in pancreatic cancer J. Exp. Clin. Cancer Res. 2012, 31, 41
33. Zeng, C.; Vangveravong, S.; McDunn, J. E.; Hawkins, W. G.; Mach, R. H. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer Br. J. Cancer 2013, 109, 2368-2377
34. Zhang, Y.; Huang, Y.; Zhang, P.; Gao, X.; Gibbs, R. B.; Li, S. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells Int. J. Nanomed. 2012, 7, 4473-4485
35. Niso, M.; Abate, C.; Contino, M.; Ferorelli, S.; Azzariti, A.; Perrone, R.; Colabufo, N. A.; Berardi, F. Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: Hints for collateral sensitivity ChemMedChem. 2013, 8, 2026-2035
36. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines Cancer Res. 1995, 55, 408-413
37. van Waarde, A.; Rybczynska, A. A.; Ramakrishnan, N.; Ishiwata, K.; Elsinga, P. H.; Dierckx, R. A. Sigma receptors in oncology: Therapeutic and diagnostic applications of sigma ligands Curr. Pharm. Des. 2010, 16, 3519-3537
38. Hornick, J. R.; Xu, J.; Vangveravong, S.; Tu, Z.; Mitchem, J. B.; Spitzer, D.; Goedegebuure, P.; Mach, R. H.; Hawkins, W. G. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine Mol. Cancer 2010, 9, 298
39. Mach, R. H.; Smith, C. R.; al-Nabulsi, I.; Whirrett, B. R.; Childers, S. R.; Wheeler, K. T. Sigma-2 receptors as potential biomarkers of proliferation in breast cancer Cancer Res. 1997, 57, 156-61
40. Barg, J.; Thomas, G. E.; Bem, W. T.; Parnes, M. D.; Ho, A. M.; Belcheva, M. M.; McHale, R. J.; McLachlan, J. A.; Tolman, K. C.; Johnson, F. E.; Coscia, C. J. In vitro and in vivo expression of opioid and sigma receptors in rat C6 glioma and mouse N18TG2 neuroblastoma cells J. Neurochem. 1994, 63, 570-574
41. Colabufo, N. A.; Berardi, F.; Contino, M.; Ferorelli, S.; Niso, M.; Perrone, R.; Pagliarulo, A.; Saponaro, P.; Pagliarulo, V. Correlation between sigma-2 receptor protein expression and histopathologic grade in human bladder cancer Cancer Lett. 2006, 237, 83-88
42. Azzariti, A.; Colabufo, N. A.; Berardi, F.; Porcelli, L.; Niso, M.; Simone, G. M.; Perrone, R.; Paradiso, A. Cyclohexylpiperazine derivative PB28, a sigma-2 agonist and sigma-1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer Mol. Cancer Ther. 2006, 5, 1807-1816
43. Kashiwagi, H.; McDunn, J. E.; Simon, P. O., Jr.; Goedegebuure, P. S.; Xu, J.; Jones, L.; Chang, K.; Johnston, F.; Trinkaus, K.; Hotchkiss, R. S.; Mach, R. H.; Hawkins, W. G. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy Mol. Cancer 2007, 6, 48
44. Peluso, J. J.; Liu, X.; Saunders, M. M.; Claffey, K. P.; Phoenix, K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1 J. Clin. Endocrinol. Metab. 2008, 93, 1592-1599
45. Kashiwagi, H.; McDunn, J. E.; Simon, P. O., Jr.; Goedegebuure, P. S.; Vangveravong, S.; Chang, K.; Hotchkiss, R. S.; Mach, R. H.; Hawkins, W. G. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma J. Transl. Med. 2009, 7, 24
46. Hornick, J. R.; Spitzer, D.; Goedegebuure, P.; Mach, R. H.; Hawkins, W. G. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands Surgery 2012, 152, S152-S156
47. Wheeler, K. T.; Wang, L. M.; Wallen, C. A.; Childers, S. R.; Cline, J. M.; Keng, P. C.; Mach, R. H. Sigma-2 receptors as a biomarker of proliferation in solid tumours Br. J. Cancer 2000, 82, 1223-1232
48. Al-Nabulsi, I.; Mach, R. H.; Wang, L. M.; Wallen, C. A.; Keng, P. C.; Sten, K.; Childers, S. R.; Wheeler, K. T. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells Br. J. Cancer 1999, 81, 925-933
49. 18F]ISO-1 PLoS One 2013, 8, e74188
50. 3]) for sigma-2 receptor tumor imaging Bioorg. Med. Chem. Lett. 2012, 22, 6352-7
51. Mach, R. H.; Dehdashti, F.; Wheeler, K. T. PET radiotracers for imaging the proliferative status of solid tumors PET Clin. 2009, 4, 1-15
52. Mach, R. H.; Zeng, C.; Tu, Z.; Jones, L. A.; Wheeler, K. T. Molecular probes for imaging the sigma-2 receptor: A receptor-based biomarker of cell proliferation. In Recent Advances of Bioconjugation Chemistry in Molecular Imaging; Chen, X., Ed.; Research Signpost: Trivandrum, 2008; pp 261-282.
53. Hou, C.; Tu, Z.; Mach, R.; Kung, H. F.; Kung, M.-P. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker Nucl. Med. Biol. 2006, 33, 203-209
54. Bowen, W. D.; Bertha, C. M.; Vilner, B. J.; Rice, K. C. CB-64D and CB-184: ligands with high sigma-2 receptor affinity and subtype selectivity Eur. J. Pharmacol. 1995, 278, 257-260
55. Søby, K. K.; Mikkelsen, J. D.; Meier, E.; Thomsen, C. Lu 28-179 labels a sigma-2 site in rat and human brain Neuropharmacology 2002, 43, 95-100
56. Mach, R. H.; Vangveravong, S.; Huang, Y.; Yang, B.; Blair, J. B.; Wu, L. Synthesis of N -substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as sigma-2 receptor ligands Med. Chem. Res. 2003, 11, 380-398
57. 2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents Bioorg. Med. Chem. 2009, 17, 1222-1231
58. 3 and sigma-2 receptor ligands Bioorg. Med. Chem. Lett. 2004, 14, 195-202
59. Tu, Z.; Dence, C. S.; Ponde, D. E.; Jones, L.; Wheeler, K. T.; Welch, M. J.; Mach, R. H. Carbon-11 labeled sigma-2 receptor ligands for imaging breast cancer Nucl. Med. Biol. 2005, 32, 423-430
60. 76Br-labeled sigma-2 receptor ligands J. Nucl. Med. 2006, 47, 1041-1048
61. 2-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer Appl. Radiat. Isot. 2010, 68, 2268-2273
62. 18F-ISO-1 J. Nucl. Med. 2013, 54, 350-357
63. 3H] N -[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)- yl)butyl]-2-methoxy-5 -methylbenzamide: A novel sigma-2 receptor probe Eur. J. Pharmacol. 2005, 525, 8-17
64. Zeng, C.; Rothfuss, J.; Zhang, J.; Chu, W.; Vangveravong, S.; Tu, Z.; Pan, F.; Chang, K. C.; Hotchkiss, R.; Mach, R. H. Sigma-2 ligands induce tumour cell death by multiple signalling pathways Br. J. Cancer 2012, 106, 693-701
65. Mach, R. H.; Wheeler, K. T. Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo Cent. Nerv. Syst. Agents Med. Chem. 2009, 9, 230-245
66. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
67. 2 receptor: A novel protein for the imaging and treatment of cancer J. Med. Chem. 2013, 56, 7137-7160
68. Zeng, C.; Rothfuss, J. M.; Zhang, Z.; Vangveravong, S.; Chu, W.; Li, S.; Tu, Z.; Mach, R. H. Functional assays to define agonists and antagonists of the sigma-2 receptor Anal. Biochem. 2014, 448, 68-74